VivoSeq
Infectious Disease

Aseptic Meningitis

4

Pipeline Programs

0

Active Trials

4

Companies Involved

Aseptic Meningitis is an early-stage landscape with 4 programs across 4 companies. The most active players are Teva, Meitheal, Glaxo Dba Glaxosmithkline. 2 therapies are approved.

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

0/100

Mech. Concentration

25/100

Completion Rate

100/100

Attrition Rate

0/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

Phase 2
No programs
Phase 3
No programs

Modality Breakdown

75%

Small molecule

3 of 4 classified programs — the dominant modality here.

25%ALL OTHERSMonoclonal antibody125%

Small molecule leads; the ring shows all 4 classified programs, each share of the total. Modality classified for 100% of 4 pipeline programs.

Trial Status

1

clinical trials

Completed1 · 100%

Trial Activity

WEUSKOP6166: Lamotrigine and Aseptic Meningitis
Completed·GSK logoGSK·N/A·NCT01657864·1 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)